Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Gwo Xi Stem Cell Applied Technology Co. Ltd. is currently navigating 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 5 distinct examiners, indicating a range of individual perspectives on the company's patent applications. Despite the number of examiners involved, the workload is contained within 2 distinct art units, suggesting that the underlying technologies share classification commonalities. The presence of 2 distinct art units requires the legal team to monitor two different sets of administrative standards.
MATALKAH, FATIMAH KHALAF is the busiest examiner for the portfolio, though this individual is only responsible for 1 pending office action. This distribution means that no single examiner holds a majority of the pending cases, as each of the 5 distinct examiners manages a portion of the 5 pending office actions. For practitioners, this requires a strategy that addresses the specific tendencies of five different individuals. The concentration in 2 distinct art units may provide some consistency in the broader examination environment even as individual examiner interactions vary.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §103 only | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| BEHARRY, ZANNA MARIA | 1 | 24.7% | +56.4% |
| MOORE, JOHN DAVID | 1 | 64.2% | +24.8% |
| BRAUN, MADELINE E | 1 | 68.0% | +25.7% |
| THUESON, HANNA MARIE | 1 | 76.7% | +28.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18126273 | METHOD FOR TREATING DEMYELINATING CONDITIONS | BRAUN, MADELINE E | 157d overdue |
| 18376459 | METHOD FOR PREPARING COMPOSITION COMPRISING MESENCHYMAL STEM CELL, EXTRACELLULAR VESICLE PRODUCED BY MESENCHYMAL STEM CELL, AND GROWTH FACTOR, COMPOSITION PREPARED BY THE METHOD, AND USE OF COMPOSITION FOR TREATING ARTHRITIS | MOORE, JOHN DAVID | 33d |
| 19012977 | PREPARATION METHOD OF PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC STROKE | MATALKAH, FATIMAH KHALAF | — |
| 18525926 | PHARMACEUTICAL COMPOSITION COMPRISING ADIPOSE TISSUE-DERIVED EXTRACELLULAR VESICLE AND BIOLOGIC AND USE OF PHARMACEUTICAL COMPOSITION FOR TREATING ARTHRITIS | BEHARRY, ZANNA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18126273 | METHOD FOR TREATING DEMYELINATING CONDITIONS | BRAUN, MADELINE E | 157d overdue |
| 18066999 | METHOD FOR STABLY AMPLIFYING PLURIPOTENT STEM CELL | THUESON, HANNA MARIE | 49d overdue |
| 18376459 | METHOD FOR PREPARING COMPOSITION COMPRISING MESENCHYMAL STEM CELL, EXTRACELLULAR VESICLE PRODUCED BY MESENCHYMAL STEM CELL, AND GROWTH FACTOR, COMPOSITION PREPARED BY THE METHOD, AND USE OF COMPOSITION FOR TREATING ARTHRITIS | MOORE, JOHN DAVID | 33d |
| 19012977 | PREPARATION METHOD OF PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC STROKE | MATALKAH, FATIMAH KHALAF | — |
| 18525926 | PHARMACEUTICAL COMPOSITION COMPRISING ADIPOSE TISSUE-DERIVED EXTRACELLULAR VESICLE AND BIOLOGIC AND USE OF PHARMACEUTICAL COMPOSITION FOR TREATING ARTHRITIS | BEHARRY, ZANNA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1638 | 3 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19012977 | PREPARATION METHOD OF PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC STROKE | MATALKAH, FATIMAH KHALAF | 1638 | §103§112 | Non-Final OA | — | Pending | Jan 08, 2025 |
| 18525926 | PHARMACEUTICAL COMPOSITION COMPRISING ADIPOSE TISSUE-DERIVED EXTRACELLULAR VESICLE AND BIOLOGIC AND USE OF PHARMACEUTICAL COMPOSITION FOR TREATING ARTHRITIS | BEHARRY, ZANNA MARIA | — | §101§102§103DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18376459 | METHOD FOR PREPARING COMPOSITION COMPRISING MESENCHYMAL STEM CELL, EXTRACELLULAR VESICLE PRODUCED BY MESENCHYMAL STEM CELL, AND GROWTH FACTOR, COMPOSITION PREPARED BY THE METHOD, AND USE OF COMPOSITION FOR TREATING ARTHRITIS | MOORE, JOHN DAVID | 1638 | §101§103 | Final Rejection | 33d | Pending | Oct 04, 2023 |
| 18126273 | METHOD FOR TREATING DEMYELINATING CONDITIONS | BRAUN, MADELINE E | 1624 | §103§112 | Final Rejection | 157d overdue | Pending | Mar 24, 2023 |
| 18066999 | METHOD FOR STABLY AMPLIFYING PLURIPOTENT STEM CELL | THUESON, HANNA MARIE | 1638 | §103 | Non-Final OA | 49d overdue | Pending | Dec 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial